Littleton, CO, October 06, 2011 --(PR.com
)-- Novus Biologicals announced today two new Lamin A+C antibodies for use in epigenetic research and for certain cancer research.
Lamins and lamin-associated proteins help shape the nucleus and provide a scaffold-type support system for chromosomes and replicating DNA to interact with epigenetic machinery. When mutations to these important proteins occur, serious familial diseases are instigated.
The lamin R453W mutation negates impairs myoblast formation and differentiation and causes Emery-Dreifuss muscular dystrophy. Research with R453W specific antibodies have indicated the mutation causes dystrophy through both a direct genetic impact, and indirect epigenetic influence over normal scaffolding functionality related to DNA replication. The lamin R482W mutation causes familial partial lipodystrophy, a disorder that causes affected individuals to be incapable of normal fat distribution, to have insulin resistance, dyslipidemia and early cardiac heart disease.
Novus’ new Lamin A + C R453W Antibody (NBP1-77401) and R482W Antibody (NBP1-77402) have been validated for use in ELISA, IP, WB, and IF staining of human cell cultures.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.